Gaithersburg, MD, May 6, 2015  – MaxCyte® Inc., the pioneer in cell therapies using scalable, highperformance cell transfection systems, announces that data generated using its flow electroporation platform will be presented at the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). There will be three podium presentations of MaxCyte co-authored abstracts.


The three presentations are:

Genome Editing of Primary Human CD34+ Hematopoietic Stem Cells Enables a Safe Harbor Targeted Gene Addition Therapeutic Strategy for Chronic Granulomatous Disease

Abstract #54

Session Info: Simultaneous Oral Abstract Sessions: Gene Editing and Gene Regulation I

Presentation Time: Wednesday, May 13, 2015, 3:30 PM

Room: Empire C


Transfection of Neutrophils from X-Linked Chronic Granulomatous Disease Patients with gp91phox mRNA Restores Oxidase Activity with High Efficiency and Viability

Abstract #298

Session Info: Simultaneous Oral Abstract Sessions: Stem Cell Engineering and Therapies II

Presentation Time: Thursday, May 14, 2015, 4:30 PM

Room: Celestin A-E


Efficient Functional Oxidase Correction after CRISPR-Oligomer Gene Repair in X-CGD Patient Hematopoietic Stem Cells (HSC) Using Non-Viral, cGMP Compliant, Scalable, Closed System

Abstract #299

Session Info: Simultaneous Oral Abstract Sessions: Stem Cell Engineering and Therapies II

Presentation Time: Thursday, May 14, 2015, 4:45 PM

Room: Celestin A-E


“These presentations will describe the use of messenger RNA transfections as a means for both transient therapeutic protein expression and genome editing-based approaches to enhancing biological activity of primary cells and stem cells to levels that may be clinically relevant,” said Madhusudan Peshwa, Executive Vice President of Cellular Therapies at MaxCyte. “The ability to engineer cells reproducibly, at clinical scale, using cGMP and regulatory compliant MaxCyte GT® Flow Transfection System permits rapid clinical translation for genome-editing technologies and engineered cell-based therapeutics.

About MaxCyte

MaxCyte is a world leader in the discovery, development, manufacture, and delivery of innovative cell-based medicines utilizing its novel best in class cell modification technology.

MaxCyte has developed a next-generation technology–MaxCyte GT® Flow Transfection System–for the rapid engineering of human cells as therapeutics, enabling the development of safer, more effective and lower cost cell-based therapies for a broad range of applications with blockbuster commercial potential. The company currently has clinical, pre-clinical-partnered, and proprietary products under development and is involved in more than a dozen clinical trials.

MaxCyte’s proprietary CARMA products utilize a universal platform for the rapid, automated loading of messenger RNA, encoding for Chimeric Antigen Receptors (CARs), into peripheral blood cells without the need for ex vivo expansion, reducing time, cost, and complexity associated with centralized manufacturing for ex vivo cell expansion-based processes. The loading of fresh patient cells with CAR mRNA harnesses immune cells for targeted killing of tumors. This anti-tumor activity is not dependent on the patient’s immune system and is independent of cell surface concentration of the tumor antigen. MaxCyte recently entered into a collaboration with The Johns Hopkins Kimmel Cancer Center to treat solid tumors with its CARMA products.

The Company also markets a portfolio of products and services that include the MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System. These platforms are used in drug discovery research and screening and protein production by 9 of the top 10 pharma companies worldwide as well as the top three in Japan. MaxCyte products enable the rapid development and consistent production of billions of (co)transfected primary cells, stem cells, and cell lines for protein and antibody production, rapid response vaccine development, and for cell-based assays with comparable results and Seamless Scalability™ from the bench to HTS and pilot and production scale.

For more information visit /